Other languages Halozyme Therapeutics, Inc.

Equities

HALO

US40637H1095

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
39.12 ^USD	+0.38%		+2.89%	+5.84%

Apr. 18	Halozyme Therapeutics Insider Sold Shares Worth $768,390, According to a Recent SEC Filing	MT
Mar. 13	Halozyme Therapeutics Insider Sold Shares Worth $839,100, According to a Recent SEC Filing	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Halozyme Therapeutics Insider Sold Shares Worth $768,390, According to a Recent SEC Filing	Apr. 18
Halozyme Therapeutics Insider Sold Shares Worth $839,100, According to a Recent SEC Filing	Mar. 13
Halozyme Therapeutics Q4 Adjusted Earnings, Revenue Rise; Reiterates 2024 Guidance	Feb. 21
Halozyme Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 20
Halozyme Therapeutics, Inc. announces an Equity Buyback for $750 million worth of its shares.	Feb. 20
Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	Feb. 20
Halozyme Therapeutics, Inc. authorizes a Buyback Plan.	Jan. 31
Halozyme Announces Takeda Receives European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy	Jan. 29
Halozyme Therapeutics Insider Sold Shares Worth $720,000, According to a Recent SEC Filing	Jan. 18
Halozyme Therapeutics Says Argenx Gets Japan's Approval for Vyvdura to Treat Certain Generalized Myasthenia Gravis Patients	Jan. 18
Halozyme Announces Argenx Receives Approval in Japan for Vyvdura®? Co-Formulated with Enhanze®? for Generalized Myasthenia Gravis	Jan. 18
Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Twelve Months Ended December 31, 2023	Jan. 17
Halozyme Therapeutics Says Roche Gets European Commission's Approval for Tecentriq SC	Jan. 16
Takeda Pharmaceutical Says US FDA Approves Hyqvia as Neuromuscular Disorder Maintenance Therapy	Jan. 16
Halozyme Announces Takeda Receives FDA Approval for Hyqvia® Co-Formulated with Enhanze® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy	Jan. 16
Halozyme Announces Roche Receives European Commission Approval of Tecentriq®? SC with ENHANZE®? Representing the EU's First Subcutaneous PD(L)1 Cancer Immunotherapy for Multiple Cancer Types	Jan. 16
Halozyme Therapeutics Insider Sold Shares Worth $800,262, According to a Recent SEC Filing	Dec. 14
Teva Pharmaceutical Unit Secures US Approval for Generic Version of Forteo	Nov. 17
Halozyme Therapeutics Insider Sold Shares Worth $788,670, According to a Recent SEC Filing	Nov. 16
Halozyme Says Argenx Obtains European Clearance of Vyvgart With Enhanze for Myasthenia Gravis	Nov. 16

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Halozyme Therapeutics, Inc.

Equities

HALO

US40637H1095

Other languages

Filters